Key facts
- It has raised $46.8M; the latest was Later Stage VC in Mar 2026.
- Notable investors include Legend Star, YuanBio Venture Capital, Leader Venture Capital, Granite Asia, GSR United Capital — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Synthgene
- ·The full record, as it builds
Funding rounds
No funding rounds for Synthgene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Synthgene
Manufacturer of life sciences raw materials designed to support research and development in biotechnology and molecular medicine. The company offers nucleic acid drug materials, cell and gene therapy inputs, immunodiagnostic materials, and mRNA-related reagents supported by advanced platforms such as antibody discovery and enzyme evolution, enabling biotechnology companies, research institutions, and diagnostic developers to accelerate therapeutic development and improve research efficiency.
- Sector
- Healthcare
- HQ
- Wuxi, China
- Founded
- 2018
- Employees
- 22
- Website
- syngenebio.com/
- Ownership
- Privately Held (backing)
Synthgene doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Synthgene shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Synthgene in its N-PORT filings yet. We sweep new filings monthly.